Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8675221 | Progress in Cardiovascular Diseases | 2018 | 10 Pages |
Abstract
Currently, there are no Class I recommendations from the American Heart Association (AHA) for the use of OM3, however, considering the safety of this therapy and beneficial findings of some modern studies (including patients with current maximal medical therapy for CVD), the AHA has recently expanded their list of Class II recommendations, in which treatment with OM3 for CVD benefit is reasonable. This review discusses the current state of the evidence, summarizes current professional recommendations, and provides recommendations for future research.
Keywords
CHDAHRQEPADPAFDAMACEASALDL-CAHAHFrEFALAAspirinMyocardial infarctionalpha-linolenic acidEicosapentaenoic aciddocosapentaenoic aciddocosahexaenoic acidOmega-3 polyunsaturated fatty acidAmerican Heart Associationcoronary heart diseasecardiovascular diseasechronic kidney diseasemajor adverse cardiovascular eventsDHADiabetes mellitusCVDFood and Drug AdministrationBlood pressureAtrial fibrillationcardiovascularheart failureheart failure with reduced ejection fractionCKDLow-density lipoprotein cholesterol
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Andrew Elagizi, Carl J. Lavie, Keri Marshall, James J. DiNicolantonio, James H. O'Keefe, Richard V. Milani,